Evidence map›Paper›PMID 39109281›Full record

ArticleFrontiers in oncology2024

Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma.

Jennifer B Permuth, Margaret A Park, Dung-Tsa Chen, Toni Basinski, Benjamin D Powers, Clement K Gwede, Kaleena B Dezsi, Maria Gomez, Shraddha L Vyas, Tiago Biachi and 46 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors.

Jennifer B PermuthDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
Margaret A ParkDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Dung-Tsa ChenDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
Toni BasinskiDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Benjamin D PowersDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Clement K GwedeDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Kaleena B DezsiDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
Maria GomezDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
Shraddha L VyasDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, United States.
Tiago BiachiDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Elena M CortizasLeonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Sylvia CrowderDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Maria Genilo-DelgadoDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
B Lee GreenDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Anna GreeneDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
Christopher GreggDepartment of Neurobiology, School of Medicine, University of Utah Health, Salt Lake City, UT, United States.
Sarah E HoffeDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Kun JiangDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, United States.
Bora KimDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Vanitha VasudevanCenter for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
Jeronimo Garcialopez De LlanoCenter for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
Anjana A MenonDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Qianxing MoDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
Lina M MorenoUrazanDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Shaffer MokDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Nathan ParkerDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Sahana RajasekharaSupportive Care Medicine, Moffitt Cancer Center, Tampa, FL, United States.
Ghulam RasoolDepartment of Machine Learning, Moffitt Cancer Center, Tampa, FL, United States.
Andrew SinnamonDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Lauren SparksTranslational Research Institute, AdventHealth, Orlando, FL, United States.
Paul A StewartDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
Kenneth TardifDepartment of Surgery, St. Anthony's Hospital, St. Petersburg, FL, United States.
Alexandra F TassielliDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Jamie K TeerDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States.
Dan Viet TranLeonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Kea L TurnerDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Susan T VadaparampilDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, United States.
Christopher J WhelanDepartment of Metabolism and Cancer Physiology, Moffitt Cancer Center, Tampa, FL, United States.
Wade G DouglasDepartment of Clinical Sciences, College of Medicine, Florida State University, Tallahassee, FL, United States.
Vic VelanovichTampa General Hospital, Tampa, FL, United States.
Andreas KarachristosTampa General Hospital, Tampa, FL, United States.
Adrian LegaspiCenter for Advanced Surgical Oncology, Palmetto General Hospital, Hialeah, FL, United States.
Kenneth MeredithDepartment of Gastrointestinal Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, United States.
Manual A Molina-VegaDepartment of Surgical Oncology, Lakeland Regional Hospital, Lakeland, FL, United States.
Kevin L HuguetDepartment of Surgery, St. Anthony's Hospital, St. Petersburg, FL, United States.
Juan P ArnolettiDepartment of Surgical Oncology, Orlando Regional Medical Center, Orlando, FL, United States.
Mark BloomstonDepartment of Surgical Oncology, Lee Health Regional Cancer Center, Fort Myers, FL, United States.
Jose TrevinoDepartment of Surgery, College of Medicine, University of Florida, Gainesville, FL, United States.
Nipun B MerchantDivision of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Jose M PimientoDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Pamela J HodulDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Mokenge MalafaDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Jason FlemingDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Sarah M JudgeDepartment of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States.
Daniel K JeongSupportive Care Medicine, Moffitt Cancer Center, Tampa, FL, United States.
Andrew JudgeDepartment of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

Introduction: Cancer-associated cachexia (CC) is a progressive syndrome characterized by unintentional weight loss, muscle atrophy, fatigue, and poor outcomes that affects most patients with pancreatic ductal adenocarcinoma (PDAC). The ability to identify and classify CC stage along its continuum early in the disease process is challenging but critical for management. Objectives: The main objective of this study was to determine the prevalence of CC stage overall and by sex and race and ethnicity among treatment-naïve PDAC cases using clinical, nutritional, and functional criteria. Secondary objectives included identifying the prevalence and predictors of higher symptom burden, supportive care needs, and quality of life (QoL), and examining their influence on overall survival (OS). Materials and methods: A population-based multi-institutional prospective cohort study of patients with PDAC was conducted between 2018 and 2021 by the Florida Pancreas Collaborative. Leveraging patient-reported data and laboratory values, participants were classified at baseline into four stages [non-cachexia (NCa), pre-cachexia (PCa), cachexia (Ca), and refractory cachexia (RCa)]. Multivariate regression, Kaplan Meier analyses, and Cox regression were conducted to evaluate associations. Results: CC stage was estimated for 309 PDAC cases (156 females, 153 males). The overall prevalence of NCa, PCa, Ca, and RCa was 12.9%, 24.6%, 54.1%, and 8.4%, respectively. CC prevalence across all CC stages was highest for males and racial and ethnic minorities. Criteria differentiated NCa cases from other groups, but did not distinguish PCa from Ca. The most frequently reported symptoms included weight loss, fatigue, pain, anxiety, and depression, with pain significantly worsening over time. The greatest supportive care needs included emotional and physical domains. Males, Black people, and those with RCa had the worst OS. Conclusions: Using clinical, nutritional, and functional criteria, nearly one-quarter of the PDAC cases in our diverse, multi-institutional cohort had PCa and 62.5% had Ca or RCa at the time of diagnosis. The PCa estimate is higher than that reported in prior studies. We recommend these criteria be used to aid in CC classification, monitoring, and management of all incident PDAC cases. Findings also highlight the recommendation for continued emotional support, assistance in alleviating pain, and supportive care needs throughout the PDAC treatment journey.

Indexed as

cancer-associated cachexiahealth-related quality of lifelongitudinal prospective cohortpancreatic adenocarcinomaracial and ethnic disparities

Identifiers

PMID39109281
PMCPMC11300308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.